Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)

摘要

Methods are provided for the treatment of a retinal disorder or optic neuritis in a subject. In some embodiments, the methods include administering a therapeutically effective amount of an MHC molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain, wherein the amino terminus of the α2 domain is covalently linked to the carboxy terminus of the α1 domain; and wherein the third domain is covalently linked to the first domain and comprises a retinal antigen or an antigen of the central or peripheral nervous system.

主权项

1. A method for treating a disorder selected from a retinal disorder and optic neuritis in a subject, comprising:
selecting a subject with a retinal disorder or optic neuritis, wherein the subject does not have uveitis or multiple sclerosis; and administering to the subject a therapeutically effective amount of a major histocompatibility complex MHC molecule comprising covalently linked first, second, and third domains, wherein the first domain is an MHC class II β1 domain and the second domain is an MHC Class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain, wherein the MHC molecule does not comprise an MHC class II α2 domain or an MHC Class II β2 domain;
wherein the third domain is covalently linked to the first domain, and wherein the third domain comprises an antigenic determinant from a retinal antigen or a myelin protein,thereby treating the retinal disorder or optic neuritis.